← All trials
NCT01341639
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Mar 1, 2013
- Completion date
- Mar 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 1250
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Sanofi-AventisLead sponsor
- MerckCollaborator
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- rotavirus vaccine, live, oral, pentavalent
- rotavirus vaccine, live, oral, pentavalent
- measles, mumps, rubella, varicella vaccine
- measles, mumps, rubella, varicella vaccine
- measles, mumps, and rubella vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.